ReviewJournal of biological engineering2026
Advances in biotechnological methods for genetic and metabolic engineering in Methylomonas sp. DH-1.
Review in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Methylomonas sp. DH-1 is a Gram-negative methanotrophic bacterium that utilizes methane as a carbon source and presents a potential chassis for sustainable production of value-added metabolites from this greenhouse gas. Realizing this potential requires the development of reliable and tailored genetic engineering methodologies. Recent progress has expanded the molecular toolbox for this strain, including optimized transformation methods to overcome host restriction barriers and plasmid-free genome engineering using cell-penetrating Cre recombinase. In addition, a tunable promoter library for tunable transcriptional control and a synthetic small regulatory RNA platform for post-transcriptional modulation of gene expression have been established. Promising complementary engineering strategies, including adaptive laboratory evolution, synthetic consortia, and systems biology approaches can be used to improve strain robustness and metabolic performance. The review highlights these advances, along with metabolic engineering efforts that have enabled the synthesis of diverse value-added chemicals in Methylomonas sp. DH-1. Collectively, these developments provide the foundation for metabolic engineering and synthetic biology in Methylomonas sp. DH-1 and may inform the design of genetic tools in other methanotrophs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.